Unity Biotechnology, INC

Unity Biotechnology, Inc. has filed for dissolution and finalized the early termination of its primary office and laboratory lease, incurring significant costs and contingent liabilities.

Unity Biotechnology, Inc. stockholders approved the company's liquidation and dissolution at a special meeting held on September 18, 2025.

Unity Biotechnology, Inc. filed an amendment to its current report, primarily to include a former address, while reiterating its plan for dissolution and the strategic issuance of a Series A Preferred Stock to facilitate the stockholder vote on the wind-down.

Unity Biotechnology, Inc. has issued a Series A Preferred Share to its sole director, granting significant voting power to align with common stockholder votes on a proposed company dissolution.

UNITY Biotechnology, Inc. has received notification of delisting from Nasdaq due to its status as a public shell with no operating business, leading the company to approve a plan for complete liquidation and dissolution.

Unity Biotechnology, Inc. has received notices from Nasdaq regarding non-compliance with minimum bid price and stockholders' equity requirements, potentially leading to delisting if not resolved by specified deadlines.

Unity Biotechnology's Q1 2025 results reveal ongoing losses and raise substantial doubt about the company's ability to continue as a going concern, despite progress in clinical trials.

Unity Biotechnology's Q3 2024 report reveals ongoing losses and substantial doubt about its ability to continue as a going concern, despite progress in clinical trials.

Unity Biotechnology, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical programs and a focus on ophthalmology.

Unity Biotechnology reported a net loss of $5.8 million for the first quarter of 2024, while continuing to advance its lead drug candidate UBX1325 through clinical trials for diabetic macular edema.

Unity Biotechnology files an amendment to its 2024 Annual Report on Form 10-K to include updated information on directors, executive officers, compensation, and related matters.

Unity Biotechnology's 10-K filing highlights the company's strategic focus on UBX1325 for ophthalmologic diseases amid financial uncertainties and a need for additional funding.

Unity Biotechnology updates its non-employee director compensation program and files its annual report on Form 10-K, detailing financial results and business activities.

CEO Anirvan Ghosh sold shares of Unity Biotechnology to cover tax withholding obligations related to vesting Restricted Stock Units.

Alexander Hieu Nguyen, CLO and Head of Operations at Unity Biotechnology, sold 17,852 shares of common stock to cover tax withholding obligations.

Lynne Sullivan, CFO of Unity Biotechnology, sold 21,867 shares of common stock on April 2, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

Alexander Hieu Nguyen, CLO and Head of Operations at Unity Biotechnology, reports the sale and acquisition of company stock and stock options.

Lynne Marie Sullivan, CFO of Unity Biotechnology, reports the acquisition of 65,000 shares of common stock and options to purchase 106,000 shares following the satisfaction of performance criteria.

Anirvan Ghosh, CEO of Unity Biotechnology, reports the acquisition of restricted stock units and stock options following the satisfaction of performance criteria.

Unity Biotechnology, Inc. is seeking stockholder approval for its complete liquidation and dissolution following the cessation of all clinical development and an inability to find viable strategic alternatives.

Unity Biotechnology, Inc. has issued a single Series A Preferred Share to its sole director, granting it 600 million votes to ensure the proportional approval of the company's planned dissolution.

Unity Biotechnology, Inc. has issued a single share of Series A Preferred Stock to its sole director, Craig R. Jalbert, with significant voting power to ensure the passage of its planned dissolution proposal.

Unity Biotechnology has filed a definitive proxy statement with the Securities and Exchange Commission.

Unity Biotechnology will hold its Annual Meeting of Stockholders virtually on June 21, 2024, to vote on director elections, auditor ratification, executive compensation, and say-on-pay frequency.

ARCH Venture Funds and their managing directors have reported a complete divestment of their beneficial ownership in Unity Biotechnology, Inc., now holding 0% of common stock.

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, has reported a 9.17% beneficial ownership stake in Unity Biotechnology, Inc., totaling 1,578,091 shares.